Systematic review and meta-analysis of the predictive power of MTHFR polymorphisms for pemetrexed drug efficacy and toxicity in non-small cell lung cancer patients

References

• Siegel RL, Miller KD, Jemal AA-O. Cancer statistics. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Parascandola M, Xiao L. Tobacco and the lung cancer epidemic in China. Transl Lung Cancer Res. 2019;8(Suppl 1):S21–S30.
   PubMedGoogle Scholar
• Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy . Semin Cancer Biol. 2018;52(Pt 1):103–109.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, WHO Panel, et al. The 2015 world health organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260.
   PubMed Web of Science ®Google Scholar
• Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764–774.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang D, Huang L, et al. Discovery of novel biomarkers of therapeutic responses in han chinese pemetrexed-based treated advanced NSCLC patients. Front Pharmacol. 2019;10(144):1–8.
   PubMedGoogle Scholar
• Adjei AA. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer. 2004;5:S51–S5.
   PubMedGoogle Scholar
• Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 2007;6(2):404–417.
   PubMed Web of Science ®Google Scholar
• Krawczyk P, Kucharczyk T, Kowalski DM, et al. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. J Cancer Res Clin Oncol. 2014;140(12):2047–2057.
   PubMed Web of Science ®Google Scholar
• Lu SC, Mato JM. S-Adenosylmethionine in cell growth, apoptosis and liver cancer. J Gastroenterol Hepatol. 2008;23 Suppl 1(Suppl 1):S73–S77.
   PubMedGoogle Scholar
• Yang H, Sadda MR, Li M, et al. S-adenosylmethionine and its metabolite induce apoptosis in HepG2 cells: Role of protein phosphatase 1 and bcl-x(S). Hepatology. 2004;40(1):221–231.
   PubMed Web of Science ®Google Scholar
• Bagley SJ, Vitale S, Zhang S, et al. Pretreatment red blood cell total folate concentration is associated with response to pemetrexed in stage IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2017;18(2):e143-9–e149.
   Web of Science ®Google Scholar
• Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011;29(9):1140–1145.
   PubMed Web of Science ®Google Scholar
• Chen JS, Chao Y, Bang YJ, et al. A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. Anticancer Drugs. 2010;21(8):777–784.
   PubMed Web of Science ®Google Scholar
• Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(12):2038–2045.
   PubMed Web of Science ®Google Scholar
• Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 2002;1:542–545.
   Web of Science ®Google Scholar
• Hiraoka M, Kagawa Y. Genetic polymorphisms and folate status. Congenit Anom (Kyoto)). 2017;57(5):142–149.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang R, Pan Y, et al. The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a Meta-analysis. BMC Cancer. 2014;14:205.
   PubMed Web of Science ®Google Scholar
• Froese DS, Huemer M, Suormala T, et al. Mutation update and review of severe methylenetetrahydrofolate reductase deficiency. Hum Mutat. 2016;37(5):427–438.
   PubMed Web of Science ®Google Scholar
• Vazquez C, Orlova M, Verzura MA, et al. Severe toxicity in adult patients with lung cancer under treatment with pemetrexed: a prospective cohort study. J Chemother. 2019;31(2):95–104.
   PubMed Web of Science ®Google Scholar
• Kang S, Zhao X, Liu L, et al. Association of the C677T polymorphism in the MTHFR gene with hemorrhagic stroke: a Meta-analysis. Genet Test Mol Biomarkers. 2013 May;17(5):412–417.
   PubMed Web of Science ®Google Scholar
• Kang S, Wu Y, Liu L, et al. Association of the A1298C polymorphism in MTHFR gene with ischemic stroke. J Clin Neurosci. 2014;21(2):198–202.
   PubMed Web of Science ®Google Scholar
• Li P, Qin C. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and susceptibility to ischemic stroke: a Meta-analysis. Gene. 2014;535(2):359–364.
   PubMed Web of Science ®Google Scholar
• Kumar A, Kumar P, Prasad M, et al. Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene (MTHFR gene) with ischemic stroke: a Meta-analysis. Neurol Res. 2015;37(7):568–577.
   PubMed Web of Science ®Google Scholar
• Ruchusatsawat K, Wongpiyabovorn J, Shuangshoti S, et al. SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis. J Mol Med. 2006;84(2):175–182.
   PubMed Web of Science ®Google Scholar
• Stern LL, Mason JB, Selhub J, et al. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers Prev. 2000;9(8):849–853.
   PubMed Web of Science ®Google Scholar
• Wu YL, Ding XX, Sun YH, et al. Methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and susceptibility to parkinson's disease: a Meta-analysis. J Neurol Sci. 2013;335(1-2):14–21. Epub 2013 Sep 12. PMID: 24064257.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71
   PubMed Web of Science ®Google Scholar
• Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses [webpage on the Internet]. Ottawa (ON): Ottawa Hospital Research Institute; 2011.
   Google Scholar
• Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28(2):123–137.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into Meta-analysis. Trials. 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Corrigan A, Walker JL, Wickramasinghe S, et al. Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations. Pharmacogenom J. 2014;14(5):411–417.
   PubMed Web of Science ®Google Scholar
• Pérez-Ramírez C, Canadas-Garre M, Alnatsha A, et al. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients. Pharmacol Res. 2016;111:877–884.
   PubMed Web of Science ®Google Scholar
• Pérez-Ramírez C, Canadas-Garre M, Alnatsha A, et al. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. Pharmacogenom J. 2019;19(2):164–177.
   PubMed Web of Science ®Google Scholar
• Kanazawa K, Yokouchi H, Wang X, Hokkaido Lung Cancer Clinical Study Group, et al. Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido lung cancer clinical study group trial (HOT) 0902. Cancer Chemother Pharmacol. 2014;74(6):1149–1157.
   PubMed Web of Science ®Google Scholar
• Tiseo M, Giovannetti E, Tibaldi C, et al. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer. 2012;78(1):92–99.
   PubMed Web of Science ®Google Scholar
• Jung M, Lee CH, Park HS, et al. Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. Yonsei Med J. 2013;54(4):854–864.
   PubMed Web of Science ®Google Scholar
• Li WJ, Jiang H, Fang XJ, et al. Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy. Oncol Lett. 2013;5(4):1165–1170.
   PubMed Web of Science ®Google Scholar
• Kucharczyk T, Krawczyk P, Powrozek T, et al. The effectiveness of pemetrexed monotherapy depending on polymorphisms in TS and MTHFR genes as well as clinical factors in advanced NSCLC patients. Pathol Oncol Res. 2016;22(1):49–56.
   PubMed Web of Science ®Google Scholar
• Lan G, Lin L, Chen X, et al. Correlation between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms and pemetrexed chemotherapy efficacy/toxicity in non-squamous non-small cell lung cancer. Med Sci Monit. 2017;23:5683–5689.
   PubMed Web of Science ®Google Scholar
• Treat J, Scagliotti GV, Peng G, et al. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials. Lung Cancer. 2012;76(2):222–227.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. JCO. 2008;26(21):3543–3551.
   PubMed Web of Science ®Google Scholar
• Li KM, Rivory LP, Clarke SJ. Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules. Br J Cancer. 2007;97(8):1071–1076.
   PubMed Web of Science ®Google Scholar
• Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. 2016;50:9–22.
   PubMed Web of Science ®Google Scholar
• Sohn KJ, Croxford R, Yates Z, et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of Colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst. 2004;96(2):134–144.
   PubMedGoogle Scholar
• Liu Y, Yin TJ, Zhou R, et al. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and Meta-analysis. Cancer Chemother Pharmacol. 2013;72(5):1125–1132.
   PubMed Web of Science ®Google Scholar
• Singh N, Baldi M, Kaur J, et al. Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: the PEMVITASTART randomized trial. Cancer. 2019;125(13):2203–2212.
   PubMed Web of Science ®Google Scholar